ZIOPHARM Oncology to Present at the 9th Annual JMP Securities Healthcare Conference

ZIOPHARM Oncology, Inc. Logo

BOSTON, June 18, 2014 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, and Francois Lebel, M.D., Senior Vice President, Clinical Development and Medical Operations will present at the 9th Annual JMP Securities Healthcare Conference on Wednesday, June 25th, 2014 at 10:00 a.m. ET at the Westin New York Grand Central in New York City.

To access a live audio webcast of the presentation, please visit the Investor Relations section at www.ziopharm.com. The webcast will be archived for 90 days.

About ZIOPHARM Oncology, Inc.:

ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression and control technology to deliver DNA for the treatment of cancer. ZIOPHARM's technology platform employs Intrexon Corporation's RheoSwitch Therapeutic System® technology to turn on and off, and precisely modulate, gene expression at the cancer site in order to improve the therapeutic index. This technology is currently being evaluated in Phase 2 clinical studies of the immune system cytokine interleukin-12 for the treatment of breast cancer and advanced melanoma. Multiple new Investigational New Drug Applications for new targets using synthetic biology technology are expected through 2015. ZIOPHARM is also developing novel small molecules as potential cancer therapeutics.

CONTACT: Lori Ann Occhiogrosso Director of Corporate Communication ZIOPHARM Oncology, Inc. 617-259-1987 locchiogrosso@ziopharm.com

Source:ZIOPHARM Oncology, Inc.